Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Promega Launches CellTiter-Glo® 3D Cell Viability Assay

Published: Thursday, June 12, 2014
Last Updated: Thursday, June 12, 2014
Bookmark and Share
Designed specifically for 3D microtissue culture.

Promega Corporation has launched a new assay validated for assessing the viability of cells in three-dimensional (3D) microtissue model systems. CellTiter-Glo® 3D Cell Viability Assay penetrates large 3D microtissue samples to provide more accurate determination of viable cells.

The assay has been validated on a range of 3D microtissue model systems, generated using scaffold and scaffold-free systems. CellTiter-Glo 3D Assay uses the robust Ultra-Glo™ Recombinant Luciferase in a solution optimized to penetrate denser 3D microtissues for a complete release of ATP and accurate assessment of viability by luminescence detection.

Scientists have found that 3D microtissue cell culture models better reproduce the cell-to-cell and cell-to-matrix interactions occurring in living organisms, providing a more predictive in vitro experimental model system.

Most, if not all commercial cell-based assays, including MTT, resazurin and current ATP assays, were developed using 2D monolayer models, are less effective on denser 3D microtissue models and cannot fully penetrate larger 3D microtissue spheroids.

"There is a clear need for cell viability assays validated for use in 3D microtissue culture. The novel chemistry of CellTiter-Glo 3D Reagent and the optimized protocol are designed specifically for these 3D model systems," says Dr. Terry Riss, Senior Product Specialist at Promega.

The CellTiter-Glo 3D Assay has a simple add-mix-incubate-measure protocol that is completed in 30 minutes or less. The reagent includes optimized detergent concentration, ATPase inhibitors for protection of released ATP, proprietary thermostable Ultra-Glo™ Recombinant Luciferase and luciferin.

CellTiter-Glo 3D Reagent acts on 3D microtissue cultures to release ATP, which is then consumed in the luciferase reaction to produce a stable glow-type luminescence.

The amount of light produced correlates with the number of viable cells in culture. The simple protocol and high sensitivity of the assay make it amenable to higher throughput screening applications.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

The Society for Biomolecular Screening Awards Promega Scientist for Innovation
High Throughput Screening Award celebrates 'twinkles in the night'.
Tuesday, September 11, 2012
Promega Signs Agreement with the Guangzhou Institute of Biomedicine and Health
The agreement is designed to co-develop compound profiling solutions for small molecule and traditional Chinese medicine drug screening.
Wednesday, April 11, 2007
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos